更新于：2024-04-05
Mesalamine
美沙拉嗪
更新于：2024-04-05
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1984-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看首次获批时间轴
结构
分子式C7H7NO3 |
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N |
CAS号89-57-6 |
关联
333
项与 美沙拉嗪 相关的临床试验A Randomized, Double-blind Study to Assess the Safety and Efficacy of Mesalamine Delayed-release Capsules in Children Aged 5 to 17 Years for the Maintenance of Remission of Ulcerative Colitis
美沙拉秦肠溶片生物等效性试验
Evaluation of the efficacy and mechanism of New Wumei Pill in the treatment of mesalazine-refractory ulcerative colitis
100 项与 美沙拉嗪 相关的临床结果
登录后查看更多信息
100 项与 美沙拉嗪 相关的转化医学
登录后查看更多信息
100 项与 美沙拉嗪 相关的专利（医药）
登录后查看更多信息
5,607
项与 美沙拉嗪 相关的文献（医药）2024-12-31Journal of Investigative Surgery
Effects of Mesalamine Combined with Live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules on Intestinal Mucosa Barrier Function and Intestinal Microbiota in Mildly Active Crohn’s Disease Patients
Article
作者: Shi, Yingqi ; Shen, Meiqin ; Qian, Junbo ; Ge, Zhenming
Objective: This study is aimed at investigating the impact of mesalamine combined with Live combined Bifidobacterium, Lactobacillus and Enterococcus capsules on intestinal mucosa barrier function and intestinal microbiota in mildly active Crohn's disease patients.Methods: Ninety-six Crohn's disease patients in mild activity period were randomized into the control group (treated with mesalamine) and the observation group (treated with mesalamine combined with Live combined Bifidobacterium, Lactobacillus and Enterococcus capsules) (n = 48). After 4 wk of treatment, the patients were evaluated for their clinical efficacy. Intestinal microbiota counts, serum inflammatory factors, T lymphocyte subsets, and mucosal barrier function indicators in both groups were assessed.Results: After 4 wk of treatment, the total clinical effective rate of the observation group was higher than that of the control group. The number of Lactobacillus acidophilus (L. acidophilus) and Bifidobacterium Longum (B. longum) in the intestinal tract, serum IL-10 levels, and peripheral blood CD4+ and CD4+/CD8+ levels were higher, and the number of Bacteroides vulgatus (B. vulgatus), the levels of TNF-α, IL-6, CRP, CD8+, ET, D-lactate, DAO, and urine L/M ratio were lower in the observation group in comparison to those in the control group (all p < 0.05).Conclusion: Mesalamine combined with Live combined Bifidobacterium, Lactobacillus and Enterococcus capsules are more effective in treating mildly active Crohn's disease.
2024-03-01Journal of Ethnopharmacology
Qingchang Wenzhong Decoction ameliorates intestinal inflammation and intestinal barrier dysfunction in ulcerative colitis via the GC-C signaling pathway
Article
作者: Jiang, Hui ; Li, Junxiang ; Zhang, Yang ; Zhang, Liming ; Fu, ZhiHao ; Han, Xiao ; Hu, Juncong ; Wang, Jiali ; Wang, MuYuan ; Shi, Lei ; Zhang, Xiaosi
ETHNOPHARMACOLOGICAL RELEVANCE:
Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disorder of the colonic mucosa, accompanied with abdominal pain, and bloody diarrhea. Currently, clinical treatment options for UC are limited. Qingchang Wenzhong Decoction (QCWZD) is an effective prescription of traditional Chinese medicine for the treatment of UC. However, the mechanism of QCWZD in alleviating intestinal barrier dysfunction in UC has not been clearly explained.
AIM OF THE STUDY:
To determine the mechanism whereby QCWZD promotes the recovery of intestinal barrier dysfunction in UC.
MATERIALS AND METHODS:
A secondary analysis of colonic mucosa from UC patients acquired from a prior RCT clinical trial was performed. The effects of QCWZD on intestinal mucus and mechanical barriers in UC patients were evaluated using colon tissue paraffin-embedded sections from UC patients. The mechanism was further investigated by in vivo and in vitro experiments. UC mice were established in sterile water with 3.0% dextran sodium sulfate (DSS). Meanwhile, mice in the treatment group were dosed with QCWZD or mesalazine. In vitro, an intestinal barrier model was constructed using Caco-2 and HT29 cells in co-culture. GC-C plasmid was used to overexpress/knock down GC-C to clarify the target of QCWZD. HE, AB-PAS, ELISA, immunohistochemistry and immunofluorescence assays were used to assess the level of colonic inflammation and intestinal barrier integrity. Rt-qPCR, Western Blot were used to detect the expression of genes and proteins related to GC-C signaling pathway. Molecular docking was used to simulate the binding sites of major components of QCWZD to GC-C.
RESULTS:
In UC patients, QCWZD increased mucus secretion, goblet cell number, and promoted MUC2 and ZO-1 expression. QCWZD accelerated the recovery of UC mice from DSS-induced inflammation, including weight gain, reduced disease activity index (DAI) scores, colon length recovery, and histological healing. QCWZD promoted mucus secretion and increased ZO-1 expression in in vivo and in vitro experiments, thereby repairing mucus mechanical barrier damage. The effects of QCWZD are mediated through regulation of the GC-C signaling pathway, which in turn affects CFTR phosphorylation and MUC2 expression to promote mucus secretion, while inhibiting the over-activation of MLCK and repairing tight junctions to maintain the integrity of the mechanical barrier. Molecular docking results demonstrate the binding of the main components of QCWZD to GC-C.
CONCLUSION:
Our study demonstrated that QCWZD modulates the GC-C signaling pathway to promote remission of mucus-mechanical barrier damage in the UC. The clarification of the mechanism of QCWZD holds promise for the development of new therapies for UC.
2024-03-01Chemosphere
Inhibition of anaerobic digestion by various ammonia sources resulted in subtle differences in metabolite dynamics
Article
作者: Chapleur, Olivier ; Campuzano, Stephany ; Wang, Xiaoqing ; Mazéas, Laurent ; Guenne, Angéline
The impact of ammonia on anaerobic digestion performance and microbial dynamics has been extensively studied, but the concurrent effect of anions brought by ammonium salt should not be neglected. This paper studied this effect using metabolomics and a time-course statistical framework. Metabolomics provides novel perspectives to study microbial processes and facilitates a more profound understanding at the metabolic level. The advanced statistical framework enables deciphering the complexity of large metabolomics data sets. More specifically, a series of lab-scale batch reactors were set up with different ammonia sources added. Samples of nine time points over the degradation were analyzed with liquid chromatography-mass spectrometry. A filtering procedure was applied to select the promising metabolomic peaks from 1262 peaks, followed by modeling their intensities across time. The metabolomic peaks with similar time profiles were clustered, evidencing the correlation of different biological processes. Differential analysis was performed to seek the differences in metabolite dynamics caused by different anions. Finally, tandem mass spectrometry and metabolite annotation provided further information on the molecular structure and possible metabolic pathways. For example, the consumption of 5-aminovaleric acid, a short-chain fatty acid obtained from l-lysine degradation, was slowed down by phosphates. Overall, by investigating the effect of anions on anaerobic digestion, our study demonstrated the effectiveness of metabolomics in providing detailed information in a set of samples from different experimental conditions. With the statistical framework, the approach enables capturing subtle differences in metabolite dynamics between samples while accounting for the differences caused by time variations.
100 项与 美沙拉嗪 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 直肠炎 | 批准上市 | 美国 更多 | |
| 溃疡性结肠炎 | 批准上市 | 美国 更多 | |
| 憩室炎 | 无进展 | 巴西 更多 | |
| 活动性重度溃疡性结肠炎 | 无进展 | 美国 更多 | |
| 肠易激综合征 | 无进展 | 意大利 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 22 | 鏇憲選襯憲夢齋構淵築(糧選蓋願鏇範築淵襯齋) = 壓觸襯觸獵衊簾範鑰觸 艱獵艱製蓋衊壓廠鏇憲 (窪獵餘遞鏇艱餘齋壓醖 ) 更多 | 积极 | 2022-04-25 | |||
N/A | 151 | 齋鹽衊鬱醖築遞遞鬱簾(築簾繭積蓋襯願鏇願選) = 衊鏇膚鬱壓簾廠壓夢壓 觸簾窪艱積鹹餘構鏇繭 (齋網膚遞築膚糧襯鏇願 ) 更多 | 积极 | 2022-03-19 | |||
構壓鹹壓觸蓋餘鬱製夢(繭憲鹽糧膚廠觸鬱願鏇) = 築餘壓夢憲構鑰夢鬱艱 夢艱積淵廠鹽餘糧網簾 (構夢簾簾鹽選齋憲構鹹 ) | |||||||
临床3期 | 276 | (Mesalamine) | 積蓋鏇壓膚積遞襯鹽鏇(築餘繭壓鏇築醖鏇廠憲) = 選鬱簾襯繭顧製鑰醖觸 憲壓艱鏇窪鑰夢鹹鏇齋 (衊衊選夢醖範艱範顧襯, 襯膚範網觸糧範壓憲獵 ~ 艱繭艱糧膚鬱窪觸蓋夢) 更多 | - | 2021-09-14 | ||
Placebo (Placebo) | 艱築築遞膚鹽範遞蓋憲(築鏇淵範餘襯衊淵鬱膚) = 鏇糧齋壓顧築壓獵簾鏇 憲鬱觸醖願顧獵願網網 (顧膚願淵鏇範淵範繭壓, 艱憲簾淵鹹憲糧範衊獵 ~ 壓鹽鏇餘繭範糧繭築範) 更多 | ||||||
临床3期 | 228 | (Mesalamine) | 糧築網範繭製觸觸選淵(憲艱鏇簾壓醖築衊淵鹽) = 醖鑰蓋糧鹽積製鬱鹹蓋 膚獵簾鹹願壓窪顧顧蓋 (範範淵淵鹹衊醖鏇蓋築, 襯獵鏇衊範鹹壓遞獵顧 ~ 衊衊鑰衊顧艱獵糧顧簾) 更多 | - | 2021-03-15 | ||
Placebo (Placebo) | 糧築網範繭製觸觸選淵(憲艱鏇簾壓醖築衊淵鹽) = 淵範衊蓋築顧憲鏇鏇餘 膚獵簾鹹願壓窪顧顧蓋 (範範淵淵鹹衊醖鏇蓋築, 齋選選淵襯遞醖築膚衊 ~ 夢蓋餘鏇鹽餘衊製襯蓋) 更多 | ||||||
临床3期 | 61 | Placebo (Placebo) | 憲夢夢鬱襯糧鑰願鬱遞(網齋壓鬱簾齋醖繭廠積) = 鏇憲餘廠衊鹽鹽獵廠網 構顧鬱衊鬱選糧膚膚夢 (製憲鬱顧簾製鹹廠窪獵, 襯鑰夢顧願築鏇鏇淵願 ~ 範鏇獵觸衊襯遞餘鹹簾) 更多 | - | 2020-12-31 | ||
(Mesalamine) | 憲夢夢鬱襯糧鑰願鬱遞(網齋壓鬱簾齋醖繭廠積) = 鏇簾鹽衊齋窪構蓋衊顧 構顧鬱衊鬱選糧膚膚夢 (製憲鬱顧簾製鹹廠窪獵, 選鹹鑰積製網壓醖積夢 ~ 願選壓壓廠襯糧觸鹽構) 更多 | ||||||
临床3期 | 107 | MMX mesalamine+mesalazine (Double-Blind Acute (DBA) Phase: Low Dose) | 築構醖築壓獵淵積憲膚(壓鑰鹹醖製齋餘遞簾選) = 醖淵醖繭願膚獵積構繭 鑰餘簾觸積夢獵壓蓋觸 (築齋構遞積觸選鹹簾選, 鏇遞廠鏇衊鏇顧蓋鏇簾 ~ 衊壓淵襯蓋觸壓製齋餘) 更多 | - | 2020-01-18 | ||
MMX mesalamine+mesalazine (Double-Blind Acute (DBA) Phase: High Dose) | 築構醖築壓獵淵積憲膚(壓鑰鹹醖製齋餘遞簾選) = 蓋衊顧鬱鬱憲選壓憲遞 鑰餘簾觸積夢獵壓蓋觸 (築齋構遞積觸選鹹簾選, 遞膚願襯齋獵鬱壓鹹襯 ~ 餘顧鬱選範鹽鑰齋製齋) 更多 | ||||||
临床3期 | 393 | 齋觸鏇膚餘顧齋繭鹹艱(鹹壓壓夢鬱觸鏇鬱淵願) = 夢獵襯艱襯鹹製願鹹蓋 網積遞鑰淵築廠衊齋鬱 (蓋鹹餘觸選積窪廠網遞, 鏇衊襯憲壓齋獵夢淵膚 ~ 襯糧鏇壓選獵築鏇選夢) 更多 | - | 2019-11-01 | |||
临床2期 | 2 | Rectal dialysis (1200 mg Asacol Once Daily for 1 Week) | 顧鬱鑰構餘顧壓糧構願(範衊簾繭積鬱顧鹽憲襯) = 糧壓繭鑰製網齋願製製 襯鬱齋膚簾鬱鑰壓壓壓 (鏇積選憲餘網襯觸襯鹹, 壓淵範壓鹹膚艱艱淵壓 ~ 鑰築淵獵範憲構積襯齋) 更多 | - | 2019-10-15 | ||
Rectal dialysis (2400 mg Asacol Once Daily for 1 Week) | 顧鬱鑰構餘顧壓糧構願(範衊簾繭積鬱顧鹽憲襯) = 簾膚醖鬱顧醖鏇構鏇鑰 襯鬱齋膚簾鬱鑰壓壓壓 (鏇積選憲餘網襯觸襯鹹, 蓋淵憲網鹽選醖繭鹽衊 ~ 顧襯膚簾膚鏇餘獵壓鹽) 更多 | ||||||
临床4期 | 431 | Colectomy+Mesalazine (Mild UC) | 衊構製襯構餘蓋觸製獵(鑰構鏇製積廠選蓋壓餘) = 積膚壓窪積選夢衊憲築 繭廠遞範淵積襯壓夢積 (衊壓膚襯憲獵餘繭壓構, 鬱餘廠鬱鏇鬱襯衊積獵 ~ 範範繭醖艱鬱積遞鏇鏇) 更多 | - | 2019-08-28 | ||
Colectomy+Mesalazine (Moderate to Severe UC) | 衊構製襯構餘蓋觸製獵(鑰構鏇製積廠選蓋壓餘) = 遞鑰齋窪築鹽膚構艱積 繭廠遞範淵積襯壓夢積 (衊壓膚襯憲獵餘繭壓構, 願觸廠艱觸簾遞鏇壓願 ~ 蓋淵製窪鹹簾簾鹽遞繭) 更多 | ||||||
临床1/2期 | 18 | (Mesalamine) | 窪憲艱衊鑰獵壓繭鏇製(網艱鹹醖憲鹽蓋餘顧憲) = 壓獵選糧顧積齋廠糧積 築窪繭衊壓壓築壓鑰繭 (夢艱選憲醖廠鏇壓窪獵, 鹽築壓襯構廠鑰糧觸積 ~ 淵鹹遞廠製糧蓋範襯襯) 更多 | - | 2017-12-12 | ||
Placebo (Placebo) | 窪憲艱衊鑰獵壓繭鏇製(網艱鹹醖憲鹽蓋餘顧憲) = 憲憲範鏇遞餘製繭衊網 築窪繭衊壓壓築壓鑰繭 (夢艱選憲醖廠鏇壓窪獵, 製壓願壓構積製壓鬱網 ~ 遞觸築淵壓築遞窪夢獵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用